FDA vs. HIMS: Why the Oral “Wegovy Copy” Crackdown Changes the GLP-1 Game
FDA’s crackdown on HIMS’s $49 compounded oral Wegovy copy reshapes GLP-1 competition after Novo Nordisk forecast 2026 sales and profit…
Sunday, February 8
Everything we published on this day.
3 stories
FDA’s crackdown on HIMS’s $49 compounded oral Wegovy copy reshapes GLP-1 competition after Novo Nordisk forecast 2026 sales and profit…
Seems like there's some interest. How much would you pay for an $APP dashboard updated 1x a week? Assuming the URL database grows over time? (AWS credits aren't cheap!)
It's Sunday morning, and here I am vibe-coding an Axon Pixel Tracker in EC2 with 0 coding abilities... Coming for you Yipit😆 $APP https://t.co/1Kyrhsll7h